DUBLIN, May 16, 2023 /PRNewswire/ — The “Bi-Specific MAbS Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the market.
The global bi-specific mabs market is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate (CAGR) of 34.9%. The bi-specific MAbs or bispecific monoclonal antibodies market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%.
Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumour immunotherapy.
The main types of bi-specific are catumaxomab (removal), blinatumomab, duligotumab, and SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types including in vivo, and in vitro are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, and others.
The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression.
For instance, in February 2022, according to the World Health Organization, a Switzerland-based international public health agency of the United Nations, cancer will be the leading cause of deaths across the globe, causing almost 10 million fatalities in 2020, or almost one in every six deaths. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer.
Additionally, in October 2022, according to the Centers for Disease Control and Prevention, chronic diseases will be among the most prevalent diseases, with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively.
The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents.
Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company.
The regions covered in the bi-specific MAbs or bispecific monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Executive Summary:
Bi-Specific MAbS Global Market Report 2023
Where is the largest and fastest growing market for bi-specific mabs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bi-specific mabs market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered
1)By Type: Catumaxomab (Removab); Blinatumomab; Duligotumab; SAR 156597
2)By Product Type: In Vivo; In Vitro
3)By Indication: Cancer; Autoimmune Diseases; Inflammatory Diseases; Infectious Diseases; Microbial Diseases; Other Indications
4)By End Use: Hospitals; Research Institutes; Other End-Users
Companies Mentioned: Johnson & Johnson; Novartis AG; Hoffmann-La Roche Ltd.; Novo Nordisk A/S; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Key Topics Covered:
1. Executive Summary
2. Bi-Specific MAbS Market Characteristics
3. Bi-Specific MAbS Market Trends And Strategies
4. Bi-Specific MAbS Market – Macro Economic Scenario
4.1 COVID-19 Impact On Bi-Specific MAbS Market
4.2 Ukraine-Russia War Impact On Bi-Specific MAbS Market
4.3 Impact Of High Inflation On Bi-Specific MAbS Market
5. Bi-Specific MAbS Market Size And Growth
5.1. Global Bi-Specific MAbS Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Bi-Specific MAbS Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Bi-Specific MAbS Market Segmentation
6.1. Global Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Catumaxomab (Removab)
- Blinatumomab
- Duligotumab
- SAR 156597
6.2. Global Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
6.3. Global Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Cancer
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Microbial Diseases
- Other Indications
6.4. Global Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hospitals
- Research Institutes
7. Bi-Specific MAbS Market Regional And Country Analysis
7.1. Global Bi-Specific MAbS Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Bi-Specific MAbS Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8. Asia-Pacific Bi-Specific MAbS Market
8.1. Asia-Pacific Bi-Specific MAbS Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
9. China Bi-Specific MAbS Market
9.1. China Bi-Specific MAbS Market Overview
9.2. China Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
10. India Bi-Specific MAbS Market
10.1. India Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11. Japan Bi-Specific MAbS Market
11.1. Japan Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12. Australia Bi-Specific MAbS Market
12.1. Australia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13. Indonesia Bi-Specific MAbS Market
13.1. Indonesia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14. South Korea Bi-Specific MAbS Market
14.1. South Korea Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15. Western Europe Bi-Specific MAbS Market
15.1. Western Europe Bi-Specific MAbS Market Overview
15.2. Western Europe Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16. UK Bi-Specific MAbS Market
16.1. UK Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17. Germany Bi-Specific MAbS Market
17.1. Germany Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18. France Bi-Specific MAbS Market
18.1. France Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19. Eastern Europe Bi-Specific MAbS Market
19.1. Eastern Europe Bi-Specific MAbS Market Overview
19.2. Eastern Europe Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20. Russia Bi-Specific MAbS Market
20.1. Russia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21. North America Bi-Specific MAbS Market
21.1. North America Bi-Specific MAbS Market Overview
21.2. North America Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22. USA Bi-Specific MAbS Market
22.1. USA Bi-Specific MAbS Market Overview
22.2. USA Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23. South America Bi-Specific MAbS Market
23.1. South America Bi-Specific MAbS Market Overview
23.2. South America Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24. Brazil Bi-Specific MAbS Market
24.1. Brazil Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25. Middle East Bi-Specific MAbS Market
25.1. Middle East Bi-Specific MAbS Market Overview
25.2. Middle East Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26. Africa Bi-Specific MAbS Market
26.1. Africa Bi-Specific MAbS Market Overview
26.2. Africa Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
27. Bi-Specific MAbS Market Competitive Landscape And Company Profiles
27.1. Bi-Specific MAbS Market Competitive Landscape
27.2. Bi-Specific MAbS Market Company Profiles
27.2.1. Johnson & Johnson
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Novartis AG
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Hoffmann-La Roche Ltd.
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Novo Nordisk A/S
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Bayer AG
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Bi-Specific MAbS Pipeline Analysis
29. Key Mergers And Acquisitions In The Bi-Specific MAbS Market
30. Bi-Specific MAbS Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Historic And Forecast Inflation Rates
31.4. Research Inquiries
31.5. About the Publisher
31.6. Copyright And Disclaimer
A selection of companies mentioned in this report includes
- Johnson & Johnson
- Novartis AG
- Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- Bayer AG
- Thermo Fisher Scientific, Inc.
- Bistro-Myers Squibb. Mylan N.V.
- Daiichi Sankyo Company, Ltd.
- Abbott
- AstraZeneca
- Eli Lilly
- Merck & Co. Inc.
- Amgen Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Roche
- Sanofi
- Genentech
- Immunomedics
- Chugai Pharmaceutical
- EMD Serono
- Emergent BioSolutions
- Jounce Therapeutics
- MarcoGenics
- Merus
- Neovii Biotech
- NovImmune SA
- OncoMed Pharmaceuticals
- Pieris
- Regeneron Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/yqcbj1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
